Copyright Reports & Markets. All rights reserved.

Global Dotinurad Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Dotinurad Tablets Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 0.5mg per Tablet
    • 1.3.3 1.0mg per Tablet
    • 1.3.4 2.0mg per Tablet
  • 1.4 Market Analysis by Technology
    • 1.4.1 Overview: Global Dotinurad Tablets Consumption Value by Technology: 2021 Versus 2025 Versus 2032
    • 1.4.2 Original Drug
    • 1.4.3 Generic Drug
  • 1.5 Market Analysis by Application
    • 1.5.1 Overview: Global Dotinurad Tablets Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.5.2 Hyperuricaemia
    • 1.5.3 Gout
    • 1.5.4 Other
  • 1.6 Global Dotinurad Tablets Market Size & Forecast
    • 1.6.1 Global Dotinurad Tablets Consumption Value (2021 & 2025 & 2032)
    • 1.6.2 Global Dotinurad Tablets Sales Quantity (2021-2032)
    • 1.6.3 Global Dotinurad Tablets Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Fuji Yakuhin
    • 2.1.1 Fuji Yakuhin Details
    • 2.1.2 Fuji Yakuhin Major Business
    • 2.1.3 Fuji Yakuhin Dotinurad Tablets Product and Services
    • 2.1.4 Fuji Yakuhin Dotinurad Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Fuji Yakuhin Recent Developments/Updates
  • 2.2 Mochida Pharmaceutical
    • 2.2.1 Mochida Pharmaceutical Details
    • 2.2.2 Mochida Pharmaceutical Major Business
    • 2.2.3 Mochida Pharmaceutical Dotinurad Tablets Product and Services
    • 2.2.4 Mochida Pharmaceutical Dotinurad Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Mochida Pharmaceutical Recent Developments/Updates
  • 2.3 Eisai
    • 2.3.1 Eisai Details
    • 2.3.2 Eisai Major Business
    • 2.3.3 Eisai Dotinurad Tablets Product and Services
    • 2.3.4 Eisai Dotinurad Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Eisai Recent Developments/Updates
  • 2.4 Ziska Pharmaceutical
    • 2.4.1 Ziska Pharmaceutical Details
    • 2.4.2 Ziska Pharmaceutical Major Business
    • 2.4.3 Ziska Pharmaceutical Dotinurad Tablets Product and Services
    • 2.4.4 Ziska Pharmaceutical Dotinurad Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Ziska Pharmaceutical Recent Developments/Updates
  • 2.5 General Pharmaceuticals
    • 2.5.1 General Pharmaceuticals Details
    • 2.5.2 General Pharmaceuticals Major Business
    • 2.5.3 General Pharmaceuticals Dotinurad Tablets Product and Services
    • 2.5.4 General Pharmaceuticals Dotinurad Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 General Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Dotinurad Tablets by Manufacturer

  • 3.1 Global Dotinurad Tablets Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Dotinurad Tablets Revenue by Manufacturer (2021-2026)
  • 3.3 Global Dotinurad Tablets Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Dotinurad Tablets by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Dotinurad Tablets Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Dotinurad Tablets Manufacturer Market Share in 2025
  • 3.5 Dotinurad Tablets Market: Overall Company Footprint Analysis
    • 3.5.1 Dotinurad Tablets Market: Region Footprint
    • 3.5.2 Dotinurad Tablets Market: Company Product Type Footprint
    • 3.5.3 Dotinurad Tablets Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Dotinurad Tablets Market Size by Region
    • 4.1.1 Global Dotinurad Tablets Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Dotinurad Tablets Consumption Value by Region (2021-2032)
    • 4.1.3 Global Dotinurad Tablets Average Price by Region (2021-2032)
  • 4.2 North America Dotinurad Tablets Consumption Value (2021-2032)
  • 4.3 Europe Dotinurad Tablets Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Dotinurad Tablets Consumption Value (2021-2032)
  • 4.5 South America Dotinurad Tablets Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Dotinurad Tablets Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Dotinurad Tablets Sales Quantity by Type (2021-2032)
  • 5.2 Global Dotinurad Tablets Consumption Value by Type (2021-2032)
  • 5.3 Global Dotinurad Tablets Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Dotinurad Tablets Sales Quantity by Application (2021-2032)
  • 6.2 Global Dotinurad Tablets Consumption Value by Application (2021-2032)
  • 6.3 Global Dotinurad Tablets Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Dotinurad Tablets Sales Quantity by Type (2021-2032)
  • 7.2 North America Dotinurad Tablets Sales Quantity by Application (2021-2032)
  • 7.3 North America Dotinurad Tablets Market Size by Country
    • 7.3.1 North America Dotinurad Tablets Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Dotinurad Tablets Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Dotinurad Tablets Sales Quantity by Type (2021-2032)
  • 8.2 Europe Dotinurad Tablets Sales Quantity by Application (2021-2032)
  • 8.3 Europe Dotinurad Tablets Market Size by Country
    • 8.3.1 Europe Dotinurad Tablets Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Dotinurad Tablets Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Dotinurad Tablets Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Dotinurad Tablets Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Dotinurad Tablets Market Size by Region
    • 9.3.1 Asia-Pacific Dotinurad Tablets Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Dotinurad Tablets Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Dotinurad Tablets Sales Quantity by Type (2021-2032)
  • 10.2 South America Dotinurad Tablets Sales Quantity by Application (2021-2032)
  • 10.3 South America Dotinurad Tablets Market Size by Country
    • 10.3.1 South America Dotinurad Tablets Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Dotinurad Tablets Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Dotinurad Tablets Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Dotinurad Tablets Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Dotinurad Tablets Market Size by Country
    • 11.3.1 Middle East & Africa Dotinurad Tablets Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Dotinurad Tablets Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Dotinurad Tablets Market Drivers
  • 12.2 Dotinurad Tablets Market Restraints
  • 12.3 Dotinurad Tablets Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Dotinurad Tablets and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Dotinurad Tablets
  • 13.3 Dotinurad Tablets Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Dotinurad Tablets Typical Distributors
  • 14.3 Dotinurad Tablets Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Dotinurad Tablets market size was valued at US$ 74.08 million in 2025 and is forecast to a readjusted size of US$ 191 million by 2032 with a CAGR of 14.6% during review period.
    Dotinurad tablets belong to a class of medications known as selective uric acid reabsorption inhibitors.They are primarily prescribed for the treatment of hyperuricemia associated with gout.By blocking URAT1,Dotinurad increases the excretion of uric acid in the urine,thereby lowering blood uric acid levels and reducing the risk of urate crystal formation in joints and tissues.
    Dotinurad is a first-in-class Selective Urate Reabsorption Inhibitor (SURI) that lowers serum uric acid levels by selectively inhibiting the URAT1 transporter in the renal proximal tubule, enhancing uric acid excretion. Developed by Eisai, it was first approved in Japan in 2020 and subsequently received marketing authorization in China in December 2024 under the brand name Urelice®. Compared to xanthine oxidase inhibitors like allopurinol and febuxostat, Dotinurad offers a differentiated safety and efficacy profile, particularly in patients with renal dysfunction or intolerance to XOIs. With over 10 million gout patients in China and limited treatment penetration, Dotinurad addresses a significant unmet clinical need. Its novel mechanism, favorable tolerability, and strategic positioning as the first SURI approved in China highlight its strong commercial potential and licensing value in the evolving urate-lowering therapy landscape.
    This report is a detailed and comprehensive analysis for global Dotinurad Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Dotinurad Tablets market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Dotinurad Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Dotinurad Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Dotinurad Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Dotinurad Tablets
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Dotinurad Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Fuji Yakuhin, Mochida Pharmaceutical, Eisai, Ziska Pharmaceutical, General Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Dotinurad Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    0.5mg per Tablet
    1.0mg per Tablet
    2.0mg per Tablet
    Market segment by Technology
    Original Drug
    Generic Drug
    Market segment by Application
    Hyperuricaemia
    Gout
    Other
    Major players covered
    Fuji Yakuhin
    Mochida Pharmaceutical
    Eisai
    Ziska Pharmaceutical
    General Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Dotinurad Tablets product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Dotinurad Tablets, with price, sales quantity, revenue, and global market share of Dotinurad Tablets from 2021 to 2026.
    Chapter 3, the Dotinurad Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Dotinurad Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Dotinurad Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Dotinurad Tablets.
    Chapter 14 and 15, to describe Dotinurad Tablets sales channel, distributors, customers, research findings and conclusion.

    Buy now